Table 1.
Disease | Ethnicity/Country | Treatment Drug(s) | Response criteria based on | Response time | N cases | References |
---|---|---|---|---|---|---|
CD | Multicentera | Infliximab | CDAIb | 2 weeks | 90 + 444 | Mascheretti et al.27 |
CD | Belgium | Infliximab | CDAIb or fistulac | 4 and 10 weeks | 245 | Vermeire et al.38 |
CD | Belgium | Infliximab | CDAIb or fistula numberc | 4 weeks | 226 | Louis et al.28 |
CD | Multicentera | Infliximab | CDAIb | 4 weeks | 90 + 444 | Mascheretti et al.26 |
CD | Belgium | Infliximab | CDAIb, fistulad, or CRPe, CRPf | 4 weeks | 145 | Louis et al.29 |
CD | Belgium | Infliximab | CDAIb or CRPg | 4 and 8 weeks | 166 | Pierik et al.30 |
CD | Belgium | Infliximab | CDAIb or fistulad or CRPh | 4 and 10 weeks | 204 | Hlavaty et al.39 |
CD | Belgium | Infliximab | CDAIb , i, fistulad, or CRPe,f | 10 weeks | 189 | Willot et al.31 |
CD | Caucasian | Infliximab | CDAIb or fistulac or CRPk | 12 weeks | 150 | Dideberg et al.32 |
CD | Caucasian | Infliximab | CDAIb, fistulad, CRPf,j | 4 and 10 weeks | 222 | Dideberg et al.33 |
CD | 95.3% Caucasian | Infliximab | CDAIb,i or fistulac or CRPe,f | 2 and 6 weeks | 344/156 | Louis et al.34 |
CD | Japan | Infliximab | CDAIi, CRPf | 4, 8 and 30 weeks | 102 | Moroi et al.35 |
CD | Caucasian (Spanish) | Infliximab | HBIk, fistulad | 10 weeks | 297 | Medrano et al.36 |
CD | Denmark | Infliximab/Adalimumab | SCTSSl | Within 22 weeks | 482 | Bank et al.25 |
CD | Slovenian | Adalimumab | IBDQm, CRPh | 4, 12, 20 and 30 weeks | 102 | Koder et al.37 |
UC | Denmark | Infliximab/Adalimumab | SCTSSl | Within 22 weeks | 256 | Bank et al.25 |
German (cohort I), North America, Europe, Canada, Israel (cohort II).
Crohn's disease activity index (CDAI); Clinical response (remission): CDAI below 150, partial response (response): drop of at least 70 CDAI points.
Fistula number: Complete response (remission): at least 50% reduction in number of fistulae from baseline at two consecutive visits.
Fistula number: Complete response (remission): complete fistula closure, partial response: at least 50% reduction in number of fistulae from baseline at two consecutive visits.
C‐reactive Protein (CRP); Biological response: drop in CRP to normal values (<3 mg/L), partial response: drop in CRP level of more than 25%.
CRP, decrease in CRP, absolute and/or relative values, among entire cohort or subgroup having elevated CRP concentrations.
CRP; Biological remission were defined as a normalisation (<3 mg/L) and biological response was defined as a >12 mg/L decrease (the mean decrease in CRP) of CRP.
C‐reactive protein (CRP); Biological response: drop in CRP to normal values (<3 mg/L) or drop in CRP level of more than 25%.
CDAI, decrease in CDAI, absolute and/or relative.
CRP; Response was defined as a drop in CRP level of more than 25% among patients with an elevated CRP before treatment (more than twice the upper limit of the normal range).
Harvey–Bradshaw index (HBI); Clinical response (remission): a final HBI lower than 4 and absence of concomitant corticosteroids, partial response (response): a decreased in HBI by more than 3 points and absence of concomitant corticosteroids.
Simple Clinical Three Step Scale (SCTSS); Response: absence or near absence of all clinical symptoms without increase in corticosteroids, Partial response: improvement or tapering of corticosteroids without worsening, nonresponse: No change or worsening of symptoms.
IBD questionnaire (IBDQ); Clinical response was defined as an increase in IBDQ of at least 22 or an IBDQ of at least 170.